特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

1型糖尿病 (若年性糖尿病) :パイプライン製品の分析

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 232787
出版日 ページ情報 英文 672 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
1型糖尿病 (若年性糖尿病) :パイプライン製品の分析 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 672 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

1型糖尿病 (若年性糖尿病) とは、膵臓がインスリンの生産を中断するという自己免疫疾患です。インスリンによって人は食物からエネルギーを得ることができます。人体の免疫系が膵臓内部のインスリン生産細胞 (β細胞) を攻撃・破壊することで発症します。主な疾病素質として、先天性疾患や家族歴、膵臓疾患、感染症などが挙げられています。主な徴候・症状には、深刻な渇きや頻繁な尿意、極度の空腹感、体重減少、倦怠感、いらつき、非日常的行動などが挙げられます。

当レポートでは、世界における1型糖尿病 (若年性糖尿病) 治療薬のパイプライン製品の開発状況について分析しており、製品開発・上市の最新動向や治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

型糖尿病 (若年性糖尿病) の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Akston Biosciences Corp, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Algiax Pharmaceuticals GmbH, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Altheia Science SRL, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ALTuCELL, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..9), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..10), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..11), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..12), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020 (Contd..1), H1 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12236IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Pipeline Review, H1 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 2, 10, 34, 28, 1, 116, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 1, 1, 31 and 4 molecules, respectively.

Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Type 1 Diabetes (Juvenile Diabetes) - Overview
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
  • Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix